Topic Name

Message

If ARUP Consult does not answer your test selection and interpretation questions, or if you would like to suggest ways to improve content or usability, please send a message to the Consult editorial staff.

Please do not include any patient-specific or personal health information (PHI) in your message.

Email Address

An email address is not required, but providing one allows the ARUP Consult editorial staff to respond directly. ARUP will only use your email address to respond to your feedback. See the ARUP privacy policy for more information regarding email use.

CAPTCHA

What code is in the image?

Enter the characters shown in the image.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Adalimumab

3017043

Adalimumab and Antibodies to Adalimumab Quantitation 3017043

About This Topic

Use Adalimumab and Antibodies to Adalimumab Quantitation (3017043) to assess the effectiveness of adalimumab (HUMIRA) drug therapy by detecting antidrug antibodies and measuring the activity of tumor necrosis factor-alpha (TNF-alpha), which is inhibited by adalimumab. Fifty percent of patients suffering from noninfectious inflammatory disorders experience treatment failure while using adalimumab.

Recommendation

Detecting treatment failure improves patient care and results in cost savings when ineffective drug therapy is recognized and halted.

Additional Information

Video

ARUP Consult

23878167

Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919-927.

Feedback

Adalimumab

23878167